99,800 Shares in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Acquired by Point72 Asset Management L.P.

Point72 Asset Management L.P. purchased a new position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 99,800 shares of the company's stock, valued at approximately $980,000. Point72 Asset Management L.P. owned about 0.17% of Ginkgo Bioworks as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. OMERS ADMINISTRATION Corp purchased a new position in Ginkgo Bioworks during the 4th quarter worth approximately $342,000. Millennium Management LLC grew its stake in Ginkgo Bioworks by 357.4% during the 4th quarter. Millennium Management LLC now owns 670,065 shares of the company's stock worth $6,580,000 after buying an additional 523,571 shares during the last quarter. Coastal Bridge Advisors LLC grew its stake in Ginkgo Bioworks by 1,609.8% during the 4th quarter. Coastal Bridge Advisors LLC now owns 276,817 shares of the company's stock worth $2,718,000 after buying an additional 260,627 shares during the last quarter. Balyasny Asset Management L.P. grew its stake in shares of Ginkgo Bioworks by 277.1% in the 4th quarter. Balyasny Asset Management L.P. now owns 80,743 shares of the company's stock valued at $793,000 after purchasing an additional 59,334 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Ginkgo Bioworks by 780.6% in the 4th quarter. Bank of America Corp DE now owns 3,764,455 shares of the company's stock valued at $36,967,000 after purchasing an additional 3,336,964 shares during the last quarter. Hedge funds and other institutional investors own 78.63% of the company's stock.

Ginkgo Bioworks Trading Down 7.2%

Shares of DNA stock opened at $7.41 on Thursday. The business's 50 day moving average is $7.24 and its two-hundred day moving average is $9.06. Ginkgo Bioworks Holdings, Inc. has a twelve month low of $5.00 and a twelve month high of $29.60. The company has a market capitalization of $433.96 million, a P/E ratio of -0.57 and a beta of 1.29.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.35). Ginkgo Bioworks had a negative net margin of 298.78% and a negative return on equity of 58.54%. The company had revenue of $48.32 million during the quarter, compared to analysts' expectations of $38.70 million. As a group, equities analysts predict that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current fiscal year.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.